| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| R&D Expense | $82.0M | +2.4% |
| SG&A Expense | $21.2M | +18.0% |
| Operating Income | -$103.2M | -5.3% |
| Income Tax | $0 | — |
| Net Income | -$97.2M | +3.3% |
| EPS (Basic) | -$0.62 | +38.0% |
| EPS (Diluted) | -$0.62 | +38.0% |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $15.5M | -56.6% |
| Current Assets | $22.9M | -41.9% |
| Total Assets | $24.1M | -41.1% |
| Current Liabilities | $30.6M | +38.1% |
| Total Liabilities | $30.7M | +36.9% |
| Stockholders' Equity | -$6.7M | -136.2% |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$85.8M | -1.2% |
| Capital Expenditures | $161K | -39.0% |
| Investing Cash Flow | -$161K | +39.0% |
| Financing Cash Flow | $65.6M | -12.0% |
| Free Cash Flow | -$86.0M | -1.1% |